SECURETEC DETEKTIONS-SYSTEME AG

Their core work

SECURETEC is a German SME that develops and manufactures detection systems, with a commercial focus on rapid substance and drug testing — primarily lateral-flow immunoassay test strips used in workplace, traffic, and clinical settings. In EU research projects, they contribute as an industry end-user and technology integrator: in INNPAPER they helped bridge printed biosensor research toward practical point-of-care diagnostics; in FITDRIVE they bring their screening and detection expertise to bear on monitoring professional drivers for fatigue and fitness impairment. Their value in a consortium is a combination of product commercialization experience and a direct route to regulated transport and safety markets.

What they specialise in

How they've shifted over time

Their early H2020 work (INNPAPER, 2018–2021) was grounded in materials and hardware: nanocellulose substrates, printed electronics, flexible biosensors, and hybridization techniques for point-of-care test devices. By their second project (FITDRIVE, 2021–2025) the focus had shifted decisively toward software-layer concerns — working patterns, behavioural profiling, neurometrics, and artificial intelligence. The underlying detection-and-screening mission stays constant, but the technical layer has moved from fabricating sensor strips to interpreting human physiological and behavioural data with AI.

SECURETEC is shifting from hardware-side biosensor R&D toward AI-powered, behaviour-based screening for transport safety — a direction that positions them squarely in the regulated professional-driver monitoring market.

How they like to work

SECURETEC has participated in both projects as a consortium partner, never as coordinator, which is consistent with an SME that joins projects to validate and eventually commercialize technology rather than to lead research agendas. With 28 unique partners across 11 countries from only two projects, they operate in mid-to-large RIA consortia and appear to connect well across borders. This profile — industry partner bringing real-world use cases and a commercial route to market — is what research-heavy consortia actively look for.

Despite just two projects, SECURETEC has built a network of 28 partners spanning 11 countries, indicating active participation in genuinely international RIA consortia rather than narrow bilateral collaborations. No geographic concentration is apparent from the data, suggesting openness to pan-European partnerships.

What sets them apart

SECURETEC sits at an unusual intersection: a commercial detection-product company (test strips, drug screening devices) that also engages in applied R&D on the sensor and AI sides of the same problem. That dual identity — product-maker and research participant — makes them a credible industry voice in consortia tackling regulated screening applications. For a partner building a project around transport safety, occupational health monitoring, or field-deployable diagnostics, SECURETEC offers a direct connection to the end-user market and regulatory pathway that purely academic partners cannot provide.

Highlights from their portfolio

• FITDRIVE
  Directly maps to SECURETEC's commercial market (professional driver screening) and marks their entry into AI and neurometric monitoring — the highest-value signal for future collaboration directions.
• INNPAPER
  Their largest funded project (€499,650) and a technically ambitious foray into nanocellulose-based printed biosensors, demonstrating willingness to engage with early-stage materials research far upstream of their core product line.